Newswise — Studies suggest that Insulin-Like Growth Factor (IGF) plays a central role in pathological growth of proliferative conditions like cancer, and may function as a resistance mechanism adopted by the majority of solid cancers following therapeutic targeting of non-IGF signaling pathways.
Last week, the journal Cell Cycle published the review article titled, “Cell Cycle Control by the Insulin-like Growth Factor Signal: At the Crossroad between Cell Growth and Mitotic Regulation.” The work comes from the longstanding expertise and collaboration of the co-authors affiliated with the ISOPROG-Somatolink Research Network and the Sbarro Institute for Cancer Research and Molecular Medicine, part of the Sbarro Health Research Organization (SHRO), at Temple University in Philadelphia, along with the Arthur Riggs Diabetes Institute and Beckmann Research Institute at City of Hope in Duarte, California.
The long missing critical overview conveyed in the article has been defined as, “a remarkable piece of work,” and, “a nice and comprehensive review [on] the cell growth/mitotic regulation by the insulin-like growth factors signal,” by its peer reviewers.
According to the authors, “the article has been specifically designed both for newcomers in the IGF biology field as well as to established researchers focusing on pathway-driven molecular targeting.
“Overall, the review aims to clarify and functionally connect established experimental findings and re-directs readers on extensively validated research on this complex molecular system and its growth/mitotic cellular network.
“Analysis suggests that IGF signal co-targeting strategies and solutions still represent an unmet objective in current pathway-driven cancer therapeutics. Consequently, a better understanding of the IGF growth/mitotic-regulatory signal remains a key goal towards more effective cancer therapies.”
See the study: https://www.tandfonline.com/doi/full/10.1080/15384101.2022.2108117
About the Sbarro Health Research Organization
The Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visit www.shro.org